NCT05038358Recruiting
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 31 Aug 2021
- Start date
- 12 Dec 2022
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Colorectal cancer
- NCT number
- NCT05038358
What you commit to
- Study type: Observational
- Planned participants: 60
- From 12 Dec 2022 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with positive HIV, HBV, HCV serology.
Other
- Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
Who the study is looking for
- Male and female over 18 years old.
- Managed at the CHUGA for a colorectal adenocarcinoma
- With an indication for immediate surgical resection as part of the care.
- Patient naive from neo-adjuvant chemotherapy
- Patient did not object to the CRC-ORGA-2 study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.